Health Robotics announces contract for its CytoCare and IV Station robots with Arabian Health Care Supply Corporation

November 2008

Italian company Health-Robotics has signed an exclusive 5-year strategic partnership with Arabian Health Care Supply Corporation (AHCSC-OLAYAN), the leading medical device provider within the Gulf Cooperation Council (GCC) countries.

OLAYAN desires to automate the preparation of life-critical hazardous and non-hazardous intraveinous (IV) admixtures with Health Robotics' CytoCare and IV Station Robots. Under this strategic partnership, AHCSC-OLAYAN will take delivery of 32 CytoCare Robots and 175 IV Station Robots up to 31 December 2013 for deployment in the Kingdom of Saudi Arabia, Kuwait, United Arab Emirates, Bahrain, Qatar, Oman, Yemen, Syria, Lebanon, Iraq, Jordan, and Palestine.

Othman Abahussein, General Manager, AHCSC-Olayan, said, "We are very pleased to have been chosen by Health Robotics as their GCC exclusive partner for these exciting new technologies. We are also proud to have been awarded the official tender process at King Faisal Specialist Hospital and Research Centre for both CytoCare and IV Station Robots.

"In addition, having had many years' experience with Pyxis, I can honestly say that IV Station has the real potential to revolutionize pharmacy automation for IVs patient doses globally."

Health-Robotics has developed and installed a totally automated system for safe preparation of patient-specific hazardous IV Admixtures in Europe, the United States of America, Asia-Pacific, and the Middle East.

The company says that while other companies have for years made promises of robotic IV automation products, and even showcased marketing demonstrations of competing solutions that were supposed to exist as far back as ten years ago, CytoCare is the only available solution that currently exists anywhere in the world to automatically compound and prepare ready-to-administer hazardous and non-hazardous IV Admixtures, and that has been proven in a "live" hospital pharmacy environment.

"Over the past year Health Robotics has significantly added to its already impressive leadership position in the sector of IV Admixtures Automation. The company has solidified its partnership with B|Braun in some European and Asia-Pacific countries; additionally, very positive dividends are beginning to emerge out of the investments we and our business partners have made with CytoCare in North America, Middle East and Japan; and lastly, the company has received an unprecedented positive response to the announcement of its non-hazardous IV medications solution IV Station. We are very pleased to be working with such serious partners as AHCSC-OLAYAN. They join a growing list of prestigious health care providers that have adopted our robotic solutions", stated Werner Rainer, CEO of Health Robotics.

"From a customer adoption perspective I would like to share that in the two years since we started this journey, we have installed more IV robots than all of our competitors have sold in over ten years of operations, and we have received purchase orders for one thousand more robots than all of our competitors combined. We are very pleased to see great progress in the hospitals' reception for CytoCare in new countries such as Germany, Australia, Japan, Taiwan, France, Belgium, Czech Republic, Saudi Arabia, United Arab Emirates, Slovakia, Austria, and also in the United States.

"I am also pleased to share that extensive tests with thousands of IV doses conducted by the University of Colorado in Denver, Rigshospitalet at the University of Copenhagen, and at Charing Cross NHS Trust in London have proven CytoCare features preventing cross-contamination and delivering sterile and extremely accurate ready-to-administer hazardous and non-hazardous IV Admixtures in the real-world hospital pharmacy environment, as opposed to our competitors who are still making ten-year old claims of studies done by themselves at their manufacturing facilities with no independent verification of such tests at any hospital pharmacy in the world," concluded Werner Rainer, CEO of Health Robotics.

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. Health Robotics announces contract for its CytoCare and IV Station robots with Arabian Health Care Supply Corporation November 2008 Italian company Health-Robotics has signed an exclusive 5-year strategic partnership with Arabian Health Care Supply Corporation (AHCSC-OLAYAN), the leading medical device provider within the Gulf Cooperation Council (GCC) countries. OLAYAN desires to automate the preparation of life-critical hazardous and non-hazardous intraveinous (IV) admixtures with Health Robotics' CytoCare and IV Station Robots. Under this strategic partnership, AHCSC-OLAYAN will take delivery of 32 CytoCare Robots and 175 IV Station Robots up to 31 December 2013 for deployment in the Kingdom of Saudi Arabia, Kuwait, United Arab Emirates, Bahrain, Qatar, Oman, Yemen, Syria, Lebanon, Iraq, Jordan, and Palestine. Othman Abahussein, General Manager, AHCSC-Olayan, said, "We are very pleased to have been chosen by Health Robotics as their GCC exclusive partner for these exciting new technologies. We are also proud to have been awarded the official tender process at King Faisal Specialist Hospital and Research Centre for both CytoCare and IV Station Robots. "In addition, having had many years' experience with Pyxis, I can honestly say that IV Station has the real potential to revolutionize pharmacy automation for IVs patient doses globally." Health-Robotics has developed and installed a totally automated system for safe preparation of patient-specific hazardous IV Admixtures in Europe, the United States of America, Asia-Pacific, and the Middle East. The company says that while other companies have for years made promises of robotic IV automation products, and even showcased marketing demonstrations of competing solutions that were supposed to exist as far back as ten years ago, CytoCare is the only available solution that currently exists anywhere in the world to automatically compound and prepare ready-to-administer hazardous and non-hazardous IV Admixtures, and that has been proven in a "live" hospital pharmacy environment. "Over the past year Health Robotics has significantly added to its already impressive leadership position in the sector of IV Admixtures Automation. The company has solidified its partnership with B\|Braun in some European and Asia-Pacific countries; additionally, very positive dividends are beginning to emerge out of the investments we and our business partners have made with CytoCare in North America, Middle East and Japan; and lastly, the company has received an unprecedented positive response to the announcement of its non-hazardous IV medications solution IV Station. We are very pleased to be working with such serious partners as AHCSC-OLAYAN. They join a growing list of prestigious health care providers that have adopted our robotic solutions", stated Werner Rainer, CEO of Health Robotics. "From a customer adoption perspective I would like to share that in the two years since we started this journey, we have installed more IV robots than all of our competitors have sold in over ten years of operations, and we have received purchase orders for one thousand more robots than all of our competitors combined. We are very pleased to see great progress in the hospitals' reception for CytoCare in new countries such as Germany, Australia, Japan, Taiwan, France, Belgium, Czech Republic, Saudi Arabia, United Arab Emirates, Slovakia, Austria, and also in the United States. "I am also pleased to share that extensive tests with thousands of IV doses conducted by the University of Colorado in Denver, Rigshospitalet at the University of Copenhagen, and at Charing Cross NHS Trust in London have proven CytoCare features preventing cross-contamination and delivering sterile and extremely accurate ready-to-administer hazardous and non-hazardous IV Admixtures in the real-world hospital pharmacy environment, as opposed to our competitors who are still making ten-year old claims of studies done by themselves at their manufacturing facilities with no independent verification of such tests at any hospital pharmacy in the world," concluded Werner Rainer, CEO of Health Robotics. Bookmark this page Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.